



A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24

Citation

Goode, Ellen L, Georgia Chenevix-Trench, Honglin Song, Susan J Ramus, Maria Notaridou, Kate Lawrenson, Martin Widschwendter, et al. 2010. "A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8q24." *Nat Genet* 42 (10) (September 19): 874–879. doi:10.1038/ng.668.

Published Version

doi:10.1038/ng.668

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:27332764>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

Published in final edited form as:

Nat Genet. 2010 October ; 42(10): 874–879. doi:10.1038/ng.668.

A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8q24

Ellen L. Goode^{1,*,#}, Georgia Chenevix-Trench^{2,*}, Honglin Song^{3,*}, Susan J. Ramus^{4,*}, Maria Notaridou⁴, Kate Lawrenson⁴, Martin Widschwendter⁴, Robert A. Vierkant¹, Melissa C. Larson¹, Susanne K. Kjaer⁵, Michael J. Birrer⁶, Andrew Berchuck⁷, Joellen Schildkraut⁷, Ian Tomlinson⁸, Lambertus A. Kiemeny⁹, Linda S. Cook¹⁰, Jacek Gronwald¹¹, Montserrat Garcia-Closas¹², Martin E. Gore¹³, Ian Campbell¹⁴, Alice S. Whittemore¹⁵, Rebecca Sutphen¹⁶, Catherine Phelan¹⁷, Hoda Anton-Culver¹⁸, Celeste Leigh Pearce¹⁹, Diether Lambrechts²⁰, Mary Anne Rossing²¹, Jenny Chang-Claude²², Kirsten B. Moysich²³, Marc T. Goodman²⁴, Thilo Dörk²⁵, Heli Nevanlinna²⁶, Roberta B. Ness²⁷, Thorunn Rafnar²⁸, Claus Hogdall²⁹, Estrid Hogdall³⁰, Brooke L. Fridley¹, Julie M. Cunningham³¹, Weiva Sieh¹⁶, Valerie McGuire¹⁶, Andrew K. Godwin³², Daniel W. Cramer³³, Dena Hernandez³⁴, Douglas Levine³⁵, Karen Lu³⁶, Edwin S. Iversen³⁷, Rachel T. Palmieri³⁸, Richard Houlston³⁹, Anne M. van Altena⁴⁰, Katja K.H. Aben⁴¹, Leon F.A.G. Massuger⁴⁰, Angela Brooks-Wilson⁴², Linda E. Kelemen⁴³, Nhu D. Le⁴⁴, Anna Jakubowska¹¹, Jan Lubinski¹¹, Krzysztof Medrek¹¹, Anne Stafford³, Douglas F. Easton⁴⁵, Jonathan Tyrer³, Kelly L. Bolton⁴⁶, Patricia Harrington³, Diana Eccles⁴⁷, Ann Chen¹⁷, Ashley N. Molina¹⁵, Barbara N. Davila¹⁵, Hector Arango⁴⁸, Ya-Yu Tsai¹⁷, Zhihua Chen¹⁷, Harvey A. Risch⁴⁹, John McLaughlin⁵⁰, Steven A. Narod⁵¹, Argyrios Ziogas¹⁸, Wendy Brewster⁵², Aleksandra Gentry-Maharaj⁴, Usha Menon⁴, Anna H. Wu¹⁹, Daniel O. Stram¹⁹, Malcolm C. Pike¹⁹, The Wellcome Trust Case-Control Consortium⁵³, Jonathan Beesley², Penelope M. Webb², The Australian Cancer Study (Ovarian Cancer)², The Australian Ovarian Cancer Study Group⁵⁴, Xiaoqing Chen², Arif B. Ekici⁵⁵, Falk C. Thiel⁵⁶, Matthias W. Beckmann⁵⁷, Hannah Yang¹², Nicolas Wentzensen¹², Jolanta Lissowska⁵⁷, Peter A. Fasching⁵⁸, Evelyn Despierre⁵⁹, Frederic Amant⁵⁹, Ignace Vergote⁵⁹, Jennifer Doherty²¹, Rebecca Hein²², Shan Wang-Gohrke⁶⁰, Galina Lurie²⁴, Michael E. Carney²⁴, Pamela J. Thompson²⁴, Ingo Runnebaum⁵, Peter Hillemanns²⁵, Matthias Dürst⁶¹, Natalia Antonenkova⁶², Natalia Bogdanova⁶³, Arto Leminen²⁶, Ralf Butzow⁶⁴, Tuomas Heikkinen²⁶, Kari Stefansson²⁸, Patrick Sulem²⁸, Sören Besenbacher²⁸, Thomas A. Sellers¹⁷, Simon A. Gayther⁴, and Paul D.P. Pharoah⁶⁵ on behalf of the Ovarian Cancer Association Consortium (OCAC)

¹Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota, USA ²The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia ³Cancer Research United Kingdom Department of Oncology University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom ⁴Department of

Address correspondence to: Dr. Simon Gayther, Gynaecological Cancer Research Laboratories, Paul O'Gorman Building, 72 Huntley Street, London, UK WC1E 6BT. UK. s.gayther@ucl.ac.uk.

*These authors contributed equally.

#A full list of author affiliations appears at the end of the paper.

Author Contributions: P.D.P.P., S.A.G., D.F.E. and A.B. designed the overall study and obtained financial support. P.D.P.P., S.A.G., S.J.R., and H.S. coordinated the studies used in Phase I and Phase II. H.S., G.C.-T., and E.L.G. coordinated Phase III. J.T. and H.S. conducted primary Phase I and Phase II analysis and Phase III SNP selection. H.S., J.B., and J.M.C. conducted Phase III genotyping, R.A.V. and M.C.L. conducted Phase III and combined data statistical analyses, and S.A.G., M.N., and K.L. designed and performed 'functional' analysis of candidate genes. E.L.G. and S.A.G. drafted the manuscript with substantial input from G.C.-T., H.S., S.J.R., T.A.S., and P.D.P.P. The remaining authors coordinated contributing studies, and all authors contributed to the final draft.

Gynaecological Oncology, University College London, EGA Institute for Women's Health, London, United Kingdom ⁵The Juliane Marie Centre, Department of Gynecology and Obstetrics, Rigshospitalet, Copenhagen, Denmark and Department of Virus, Hormones and Cancer Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark ⁶Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA ⁷Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina, USA ⁸Centre for Molecular Oncology & Imaging, Institute of Cancer, Barts and The London School of Medicine and Dentistry, London, United Kingdom ⁹Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands ¹⁰Division of Epidemiology and Biostatistics, University of New Mexico, Albuquerque, New Mexico and Alberta Health Services-Cancer Care, Calgary, AB, Canada ¹¹International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, ul. Polabska 4, 70-115 Szczecin, Poland ¹²Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA ¹³The Royal Marsden Hospital, Gynecological Oncology Unit, Fulham Road, London SW3 6JJ, United Kingdom ¹⁴Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia ¹⁵Division of Epidemiology and Biostatistics, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California, USA ¹⁶University of South Florida, Pediatrics Epidemiology Center, College of Medicine, Tampa, Florida, USA ¹⁷H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA ¹⁸Department of Epidemiology, School of Medicine, University of California, Irvine, California ¹⁹University of Southern California, Department of Preventive Medicine, Keck School of Medicine, Los Angeles, California, USA ²⁰Vesalius Research Center, VIB and K.U. Leuven, Belgium ²¹Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA ²²Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Germany ²³Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York, USA ²⁴University of Hawaii, Cancer Research Center, Honolulu, Hawaii, USA ²⁵Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany ²⁶Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland ²⁷University of Texas School of Public Health, Houston, Texas, USA ²⁸deCODE Genetics, Sturlugata 8, 101 Reykjavik, Iceland ²⁹The Juliane Marie Centre, Department of Gynecology and Obstetrics, Rigshospitalet, Copenhagen, Denmark ³⁰Department of Virus, Hormones and Cancer Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark ³¹Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA ³²Women's Cancer Program, Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA ³³Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts, USA ³⁴National Institutes of Aging, National Institutes of Health, Bethesda, Maryland, USA ³⁵Memorial Sloan-Kettering Cancer Center, New York, New York, USA ³⁶MD Anderson Cancer Center, Houston, Texas, USA ³⁷Department of Statistics, Duke University, Durham, North Carolina, USA ³⁸Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA ³⁹Molecular and Population Genetics Team, The Institute of Cancer Research: Royal Cancer Hospital, London, United Kingdom ⁴⁰Department of Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands ⁴¹Comprehensive Cancer Centre East, Nijmegen, The Netherlands ⁴²Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada and Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada ⁴³Alberta Health Services-Cancer Care, Calgary, AB, Canada ⁴⁴Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada ⁴⁵Cancer Research United Kingdom Genetic Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom ⁴⁶Department of Public Health and Primary Care, Strangeways Research Laboratory, University

of Cambridge, Cambridge, United Kingdom ⁴⁷University of Southampton School of Medicine, WCGS Princess Anne Hospital, Southampton SO16 5YA, UK ⁴⁸West Coast Gynecologic Oncology, Clearwater, Florida, USA ⁴⁹Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, Connecticut, USA ⁵⁰Cancer Care Ontario, Toronto, Canada ⁵¹Women's College Research Institute, University of Toronto, Canada ⁵²Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA ⁵³A full list of WTCC authors is given in Supplementary note 1 in the supplementary data ⁵⁴Peter MacCallum Cancer Institute, Melbourne, Australia ⁵⁵Institute of Human Genetics, Friedrich Alexander University Erlangen Nuremberg, Erlangen, Germany ⁵⁶University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany ⁵⁷Department of Cancer Epidemiology and Prevention, The M. Sklodowska-Curie Cancer Center and Institute of Oncology, WH Roentgena 5, 00-782 Warsaw, Poland ⁵⁸Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA ⁵⁹Department of Gynaecologic Oncology, University Hospitals Leuven, Belgium ⁶⁰Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany ⁶¹Clinics of Obstetrics and Gynaecology, Friedrich Schiller University, Jena, Germany ⁶²Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., Minsk, Belarus ⁶³Byelorussian Institute for Oncology and Medical Radiology Aleksandrov N.N., Minsk, Belarus and Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany ⁶⁴Department of Obstetrics and Gynecology and Department of Pathology, Helsinki University Central Hospital, Helsinki, Finland ⁶⁵Cancer Research United Kingdom Department of Oncology and Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom

Abstract

Ovarian cancer (OC) accounts for more deaths than all other gynecological cancers combined. To identify common low-penetrance OC susceptibility genes, we conducted a genome-wide association study (GWAS) of 507,094 SNPs in 1,768 cases and 2,354 controls, with follow-up of 21,955 SNPs in 4,162 cases and 4,810 controls, leading to the identification of a confirmed susceptibility locus at 9p22 (*BNC2*)¹. Here, we report on nine additional candidate loci ($p \leq 10^{-4}$), identified after stratifying cases by histology, genotyped in an additional 4,353 cases and 6,021 controls. Two novel susceptibility loci with $p \leq 5 \times 10^{-8}$ were confirmed (8q24, $p = 8.0 \times 10^{-15}$ and 2q31, $p = 3.8 \times 10^{-14}$); two additional loci were also identified that approached genome-wide significance (3q25, $p = 7.1 \times 10^{-8}$ and 17q21, $p = 1.4 \times 10^{-7}$). The associations with serous OC were generally stronger than other subtypes. Analysis of *HOXD1*, *MYC*, *TiPARP*, and *SKAP1* at these loci, and *BNC2* at 9p22, supports a functional role for these genes in OC development.

Invasive epithelial OC is a rare but often lethal disease. Individuals with an OC family history have approximately a two-fold increased risk, even after accounting for mutations in known highly-penetrant susceptibility genes, suggesting that other risk alleles await identification. GWAS have identified common genetic variants influencing risks for a range of cancers, including our recent identification of low-risk OC alleles at 9p22.2¹. The most significant association conferred a 20% reduction in risk with each copy of the minor allele; this association was stronger for serous subtype, suggesting that disease heterogeneity may have reduced the power of our GWAS¹. To identify further susceptibility alleles, we have followed-up additional candidate loci from that study after stratifying cases by histological subtype.

Our GWAS was performed for women of European ancestry diagnosed with the major histological subtypes of invasive epithelial OC: serous, mucinous, endometrioid, and clear cell (Table 1, Supplementary Table 1). Phase I included 1,768 cases and 2,354 controls from the UK genotyped using the Illumina Infinium 610K and 550K arrays, respectively. Data were available for 507,094 genotyped SNPs and 1,549,784 imputed SNPs from HapMap. The top-ranked 21,955 SNPs, selected based on analysis of all subtypes combined, were genotyped in an additional 4,162 cases and 4,810 controls in Phase II leading to the identification of a compelling association near the *basonuclin 2* (*BNC2*) gene at 9p22.2 ($p=5.4\times 10^{-22}$, rs3814113 for serous subtype)¹. Quantile-quantile (Q-Q) plots of the distribution of test statistics to compare genotype frequencies in cases versus controls in the stage 1 and stage 2 data, suggested there was little evidence of any general inflation of the test statistics (estimated inflation factor $\lambda_{1000} = 1.026$ and 1.0086 respectively based on the bottom 90% of the distribution)¹.

In the current study, combined Phase I and Phase II data from this GWAS were re-analyzed overall and restricting to 'serous only'. This revealed nine loci with a p -value $\leq 10^{-4}$ for all subtypes (1p31, 1p36, 2q31, 11p14, and 17q21) and/or for serous subtype (2p22, 3q25, 7p21, and 8q24). Thirty SNPs from these loci were genotyped in an additional 4,353 cases and 6,021 controls in Phase III; thus, data were available for combined analysis of 10,283 cases (including 5,841 serous) and 13,185 controls. In addition, results on an independent 194 cases and 40,933 controls were incorporated using metaanalyses. There was little additional evidence of association for five loci in either the Phase III or combined data, although trends in association were in the same direction for some SNPs (Supplementary Table 2; Supplementary Table 3). For SNPs at two loci (2q31, 8q24), there was strong support for associations in the Phase III data alone ($p < 0.001$) and in the combined analyses of all cases or serous cases only ($p \leq 5 \times 10^{-8}$). At two other loci, 3q25 and 17q21, there was good evidence for associations in the combined analysis of serous cases, but these did not quite reach genome wide significance ($p = 7.1 \times 10^{-8}$ and $p = 1.4 \times 10^{-7}$ respectively). No heterogeneity across studies was observed ($p > 0.05$); these data are summarized in Table 2, Figure 1 and Supplementary Figure 1).

At the 8q24 locus, the minor allele of rs10088218 was associated with a decreased risk (Table 2), with the association being more significant for serous subtype (odds ratio, OR, 0.76; 95% confidence intervals, 95% CI, 0.70-0.81; $p = 8.0 \times 10^{-15}$); the additional 8q24 SNPs rs1516982 ($r^2 = 0.46$) and rs10098821 ($r^2 = 0.80$) were also highly significant (Supplementary Table 2). The minor allele of rs2072590 at 2q31 was associated with an increased risk which was primarily significant for serous subtype (OR 1.20, 95% CI 1.14-1.25, $p = 3.8 \times 10^{-14}$); more significant results were also seen for serous subtype for minor alleles of rs2665390 at 3q25 (OR 1.24, 95% CI 1.15-1.34, $p = 7.1 \times 10^{-8}$) and rs9303542 at 17q21 (OR 1.14, 95% CI 1.09-1.20, $p = 1.4 \times 10^{-7}$).

We observed significant heterogeneity for associations at the 8q24 and 2q31 loci when cases were stratified into four histological subtypes ($p = 2.9 \times 10^{-4}$ for rs2072590, $p = 1.1 \times 10^{-7}$ for rs10088218) (Table 2). For both loci, the trends in association for endometrioid and mucinous OC were in the same direction as serous cases, but there was no evidence of association at either locus in clear cell OC. To a lesser degree, a difference in risk by subtype was also observed at 3q25 ($p = 0.02$ for rs2665390). We also examined SNP associations by age and family history of OC in first-degree relatives. No differences in risk were observed by age (Supplementary Table 4) and, among the four novel loci, no interactions by family history were observed (Supplementary Table 5).

We also tested the most significant risk-associated SNPs at 8q24, 2q31, 3q25 and 17q21 for association with overall survival after a diagnosis of OC, in 'all' case and 'serous only' case

subgroups. For the latter group, we also performed an analysis adjusting for tumor stage and grade. We found borderline evidence for an association with survival at 17q21 in all cases (HR=1.06, 95% CI 1.00-1.13, P=0.04) and in serous only cases (HR=1.08, 95% CI 1.00-1.16, P=0.04). This effect was not greatly attenuated when adjusting for stage and grade amongst serous cases (HR=1.06, 95% CI 0.97-1.15, P=0.15). There was no evidence of association with survival at 8q24, 2q31 and 3q25.

We used Pupasuite (<http://pupasuite.bioinfo.cipf.es/>) for *in silico* analyses of risk-associated and strongly-correlated SNPs ($r^2 > 0.80$) in the four loci but failed to find compelling evidence for any functional role (Supplementary Table 6). Genotyping of additional SNPs identified from HapMap and the 1,000 Genomes Project (<http://www.1000genomes.org/page.php>) is required to fine-map these loci to identify both causal variants and target genes. Even so, known genomic architecture may provide some insights into functional mechanisms underlying OC susceptibility. For example, common variants at 8q24 have previously been shown to confer susceptibility to multiple cancer phenotypes including prostate, colorectal, breast, and bladder cancers²⁻⁷, and previous functional studies suggest that common variants may be associated with transcriptional regulation of *MYC*^{8,9}. Most risk associations at 8q24 are located 5' of *MYC*; but the three most significant SNPs for OC lie >700 kb 3' of *MYC* in an apparent gene desert, suggesting either that *MYC* is not the target gene for OC, or possibly that variants in this region are also capable of distant regulation of *MYC* (Figure 1a).

rs2665390 at 3q25 is intronic to the *TiPARP* gene; there are no other candidate genes within 200 kb of this SNP (Figure 1b). *TiPARP* is a poly (ADP-ribose) polymerase (PARP)¹⁰ and is a particularly intriguing candidate gene for OC for two reasons. First, recent reports show that *BRCA1/2* deficient cells survive by using PARP1 as an alternative DNA repair mechanism¹¹. This has led to the development of a novel therapy based on synthetic inhibition of PARP1 for breast and ovarian cancer patients carrying *BRCA1* or *BRCA2* mutations¹². Second, *TiPARP* is inducible by dioxin¹³, raising the hypothesis that this environmental contaminant may influence OC risk among susceptible women.

The 2q31 locus contains a family of homeobox (HOX) genes involved in regulating embryogenesis and organogenesis (Figure 1c). Altered expression of HOX genes has been reported in many cancers^{14,15}. The OC risk-associated SNP rs2072590 lies in non-coding DNA downstream of *HOXD3* and upstream of *HOXD1*, and it tags SNPs in the *HOXD3* 3' UTR. Both genes have been implicated in neoplastic development^{16,17}.

Finally, associated and correlated SNPs at 17q21 are intronic to *SKAP1*, which has strong homology to the *SRC* oncogene at the C-terminal end (Figure 1d). *SKAP1* regulates mitotic progression, specifically at the transition of metaphase to anaphase¹⁸. In T-cells, constitutive expression of *SKAP1* suppresses activation of *RAS* and *RAF1*, both of which have been implicated in the early stage development of OC¹⁹.

We evaluated risk-associated SNPs and candidate genes from these four novel loci, as well as from *BNC2*¹, for evidence of a functional role in OC development by examining genotype associated gene expression for *BNC2* (9p22), *MYC* (8q24), *TiPARP* (3q25), *HOXD1* and *HOXD3* (both at 2q31), and *SKAP1* (17q21). We found no evidence of genotype associated gene expression in an analysis of 48 normal primary human ovarian surface epithelial (POE) cell cultures (Supplementary Table 7) although power was limited due to the relatively small numbers. We also compared the expression of each of the five candidate genes between 48 POE and 24 OC cell lines and found highly-significant differences in gene expression between normal and cancer cells for *BNC2*, *TiPARP*, *HOXD1*, and *SKAP1* (Figure 2;

Supplementary Figure 2). These data suggest that *BNC2* and *TiPARP* have a loss-of-function role, and that *HOXD1* and *SKAP1* have a gain-of-function role in OC development.

Gene expression was also examined in an *in vitro* model of OC initiation and progression established through oncogenic expression of *MYC* and mutant *KRAS*^{G12V} in POE cells (Figure 2; Supplementary Table 9). We found that *BNC2* and *TiPARP* expression decreases, and *SKAP1* expression increases, with neoplastic development, consistent with the expression of these genes in POE versus OC cells. We also investigated gene expression for 216 primary serous OC samples analysed by The Cancer Genome Atlas Project (<http://cancergenome.nih.gov>). These data support frequent loss of *BNC2* and *TiPARP* and gain of *HOXD1* expression in OC development (Supplementary Figure 3).

In summary, we report two confirmed novel common low-penetrance OC susceptibility loci, and a further two candidate susceptibility loci, adding to a growing list that includes *BNC2* and the 19p13 locus presented in an accompanying report by Bolton and colleagues. All six susceptibility loci suggest possible functional relevance of candidate genes that could plausibly be involved in OC development and aid in our understanding of disease aetiology. Strikingly, these data also suggest that common germline variation influences the clinico-pathological development of disease, as previously reported for the highly-penetrant (*BRCA1* and *BRCA2*) germline variants²⁰.

Methods

Phase I and II

As described previously¹, Phase I self-reported white European participants were from four collections of invasive epithelial OC cases and two collections of controls^{22,23} (Supplementary Table 1). Logistic regression and linear trend tests examined SNP associations (including imputed genotypes) using imputed genotype weights and ethnicity-related principal components. Phase II SNPs were selected based on Phase I ranked test statistics (all, serous) weighted by imputation status and accuracy (r^2)²⁴ and design score, and participants were of European ancestry from 12 studies. Logistic regression adjusted for a HapMap-based ancestry score²⁵ and an ancestry-informative-marker-based principal component.

Phase III

Sixteen studies contributed invasive epithelial OC cases and controls of European ancestry (Supplementary Table 1). Nine loci (30 SNPs, Supplementary Table 9) were selected based on test statistic rankings from combined Phase I and Phase II analyses ($p < 10^{-5}$ in all or serous cases). Eleven studies used Taqman (two SNPs) and Sequenom MassARRAY (remaining SNPs). Data for four studies were available from a genome wide scan using the same Illumina Infinium 610K array that was used in Phase 1 excluding samples with call rate <95%, >1% discordance, <80% European ancestry, or ambiguous gender. For one study, Illumina Infinium 317K data were used with imputation based on HapMap CEU data following 100 iterations in MACH version 1.0.16, excluding SNPs with $r^2 < 0.30$. For one study, cases and ~2,900 controls were genotyped on a Centaurus (Nanogen) platform (excluding SNPs with >1.5% HapMap mismatch), and additional control data used the Illumina Infinium 317K and HumanCNV370-duo Bead Arrays; per-SNP call rate was >97%, and concordance was >98.5%. Logistic regression modeled the number of observed or imputed minor alleles; no confounding by age was observed. Combined analyses adjusted for study and tested heterogeneity with Cochran's Q statistic and I^2 values. Effect modification and differences in risk by subtype were tested with interaction terms and

polytomous regression, respectively. Summary-level data was available for the ICE study; thus meta-analytic techniques fitted fixed and random effects^{26,27}.

Genotyping Quality Control Measures—The Ovarian Cancer Association Consortium (OCAC) has established robust genotyping quality control (QC) guidelines to ensure accurate genotyping, particularly across multiple studies. Data included must pass the following quality control criteria: (1) > 3% sample duplicate samples included in each study; (2) samples from cases and controls mixed on 384 well plates; (3) samples that consistently fail (e.g. for >20% of all SNPs) are removed; (4) genotype data for a SNP are removed if call rates > 90% for each individual 384-well plate, but if > 25% plates from any site are excluded for this reason then all the data from that site are excluded; (5) the overall call rate for a SNP for each study > 95%, which is calculated after ineligible samples and plates are excluded; (6) genotyping concordance rates for the duplicates >98%; (7) Hardy Weinberg Equilibrium (HWE) in White European controls must be $P \geq 0.005$. If $HWE P = 0.05-0.005$ the genotyping clustering quality is reviewed by members of the OCAC genotyping committee (PDP; GC-T, SJR, HS) before inclusion. In addition, as part of overall QC, genotyping consistency across labs is evaluated by genotyping a panel of CEPH-Utah trios including 90 individual DNA samples, 5 duplicate samples and 1 negative control (http://ccr.coriell.org/Sections/Search/Panel_Detail.aspx?PgId=202&Ref=HAPMAPPT01). Genotyping concordance between centres has to be > 98% in order for the genotype data to be included. Genotyping QC for Phase 1 and Phase 2 of the GWAS have been described previously¹.

Genotyping QC in the current study: In Phase 1, 507,094 out of 540,573 SNPs (94%) passed QC. In both Phase 1 and Phase 2 duplicate concordance rates were 99.9%. For phase 3 the data from the five studies using GWAS data met the following overall quality control criteria: (1) Caucasian and greater than 80% European Ancestry; (2) Sample call rate $\geq 95\%$; (3) SNP call rate $\geq 95\%$; (3) 100% concordance of duplicates (81 replicate pairs) (4) HWE for each SNP $P \geq 10^{-4}$. The Sequenom and Taqman data met the OCAC criteria described above. The results from Phase 3 genotype QC for each of the 30 SNPs are summarized in supplementary table 10.

Survival Analysis

Among the study participants, 7,222 cases had survival time information available and 2,791 died within five years after diagnosis. The effect of the 8q24, 2q31, 3q25 and 17q21 loci on time to all-cause mortality after EOC diagnosis was assessed using Cox regression stratified by study and modeling the per-allele effect as log-additive. Because the EOC cases showed a variable time from diagnosis to study entry, we allowed for left truncation with time at risk starting on date of diagnosis and time under observation beginning at the time of study entry. The analysis was right censored at 5 years after diagnosis in order to reduce the number of non-EOC related deaths.

Gene Expression Analysis in POE and OC Cell Lines

Normal POE cell lines were established from brushings of histologically-confirmed disease-free ovaries from total hysterectomies at University College London Hospital, UK; short-term cultures were established as previously described²⁸. The non-neoplastic status and epithelial (non-fibroblastic) nature of cells was confirmed by staining for CA125, CK7, FVIII, and FSP. RNA was extracted from POE and OC cell lines (Supplementary Table 11) using RNeasy Mini Kits (QIAGEN). Reverse transcribed (RT) RNA was analysed for expression by semi-quantitative real-time PCR using the Applied Biosystems 7900HT genetic analyzer. Gene expression was normalized against the endogenous controls glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β -actin. Real time expression

data were analysed using the comparative Delta-Delta Ct method. Expression values of all cell lines were generated relative to either the lowest or highest expression of a POE cell line, normalized against GAPDH and β -actin. Differences in the relative expression of each candidate gene between OC and POE cell lines were assessed using a nonparametric Wilcoxon Rank sum test. For allele-specific expression analysis, expression was calculated relative to the average expression of common homozygotes for each SNP normalized against the expression of the endogenous control genes; linear regression and Wilcoxon Rank sum tests assessed difference in expression across genotypes.

An *in vitro* Genetic Model of Neoplastic Transformation in Normal Ovarian Epithelial Cells

Methods used for the immortalization of ovarian epithelial cells and over-expression of *MYC* (iOE^{cm_yc}) are described elsewhere²⁹. All cell lines were grown in NOSE-CM²⁸. Using FuGene6 (Roche), iOE^{cm_yc} cell lines were transfected with pcDNA3.1.neo.KRAS^{G12V} (Addgene) to create cell lines stably expressing a mutant form of *KRAS* (*KRAS*^{G12V}). *KRAS*^{G12V} expression was confirmed by RFLP-PCR. Mutant allele expression was confirmed by RFLP-PCR. Anchorage-independent growth assays were performed as previously described³⁰. To test invasiveness, 0.125×10^6 cells were resuspended in serum-free medium and added to rehydrated invasion membranes (Millipore) for 24 hours. 10% serum (Invitrogen) was added to the lower chamber as a chemo-attractant. Invaded cells were lysed, stained with a fluorimetric dye, and analysed on a Varioskan platereader (Thermo). To culture cells in 3D, tissue culture plastics were coated twice with 1.5% polyHEMA dissolved in 95% ethanol and cultured for 14 days. For immunohistochemistry, spheroids were fixed in neutral buffered formalin (VWR), processed into paraffin and stained for MIB1 or WT1 using standard techniques. For microarray analyses, RNA was extracted from spheroids using the QIAgen RNeasy kit (Qiagen), and experiments used the Illumina HT-12 BeadChip platform (Illumina).

Acknowledgments

We thank all the individuals who took part in this study. We thank all the researchers, clinicians and administrative staff who have enabled the many studies contributing to this work. In particular we thank A. Ryan and J. Ford (UKO); J. Morrison, P. Harrington and the SEARCH team (SEA), U. Eilber and T. Koehler (GER); D. Bowtell, A. deFazio, D. Gertig, A. Green, A. Green, P. Parsons, N. Hayward, D. Whiteman (AUS); L. Gacucova (HMO); S. Haubold, P. Schürmann, F. Kramer, W. Zheng, T.-W. Park-Simon, K. Beer-Grondke and D. Schmidt (HJO); L. Brinton, M. Sherman, A. Hutchinson, N. Szeszenia-Dabrowska, B. Peplonska, W. Zatonski, A. Soni, P. Chao, M. Stagner (POL1). The genotyping and data analysis for this study was supported by a project grant from Cancer Research UK. We acknowledge the computational resources provided by the University of Cambridge (CamGrid). This study makes use of data generated by the Wellcome Trust Case-Control consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113. The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund thanks to donations by the family and friends of Kathryn Sladek Smith.

The MAL study is supported by grants from Mermaid 1, The Danish Cancer Society and National Cancer Institute, Bethesda, USA (R01-CA-61107). The MAY study and Phase III/combined analyses were supported by the National Institutes of Health, National Cancer Institute grants R01-CA-122443 and funding from the Mayo Foundation. The PBCS was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The Fox Chase Cancer Center ovarian cancer study, part of the NCI collaboration, is supported by an Ovarian Cancer SPOR (P50 CA083638). The NCO study is supported by the National Institutes of Health, National Cancer Institute grant R01-CA-76016. The SEA study is funded by a programme grant from Cancer Research UK; we thank the SEARCH team and the Eastern Cancer Registration and Information Centre for patient recruitment. The TBO study was supported by the National Institutes of Health (R01-CA106414); American Cancer Society (CRTG-00-196-01-CCE); Advanced Cancer Detection Center Grant, Department of Defense (DAMD17-98-1-8659). The TOR study was supported by grants from the Canadian Institutes for Health Research, the National Cancer Institute of Canada with funds provided by the Canadian Cancer Society, and the National Institutes of Health (R01-CA-63682 and R01-CA-63678). Additional support for the TOR, NCO, MAY, TBO, and NCI studies was provided by R01-CA-114343. The UCI study is supported by the National Institutes of Health, National Cancer Institute grants CA-58860, CA-92044 and the Lon V Smith

Foundation grant LVS-39420. The UKO study is supported by funding from Cancer Research UK, the Eve Appeal, and the OAK Foundation; some of this work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre funding scheme; and we particularly thank Ian Jacobs, Eva Wozniak, Andy Ryan, Jeremy Ford and Nayala Balogun for their contribution to the study. The AUS study is supported by the National Health and Medical Research Council of Australia (199600), U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729 (Award no. W81XWH-06-1-0220), and the Cancer Council Tasmania and Cancer Foundation of Western Australia; GCT and PW are Research Fellows of the National Health and Medical Research Council; the Australian Ovarian Cancer Study (AOCS) Management Group (D Bowtell, G Chenevix-Trench, A deFazio, D Gertig, A Green, and PM Webb) gratefully acknowledges the contribution of all the clinical and scientific collaborators (see <http://www.aocstudy.org/>); the Australian Cancer Study (ACS) Management Group comprises A Green, P Parsons, N Hayward, PM Webb, and D Whiteman. The BAV study is supported by the ELAN Foundation and Erlangen University Hospital. The BEL study is supported by the National Cancer Plan - Action 29 for the support of Translational Research. The DOV study (Seattle Diseases of the Ovary) was supported by the US. NIH grants R01-CA-112523 and R01-CA-87538. The GER study was supported by the German Federal Ministry of Education and Research of Germany; Programme of Clinical Biomedical Research (01 GB 9401); genotyping in part by the state of Baden-Württemberg through the Medical Faculty, University of Ulm (P.685); and data management by the German Cancer Research Center. The HAW study was supported by US Public Health Service grant R01-CA-58598 and contracts N01-CN-55424, N01-PC-67001, and N01-PC-35137 from the National Cancer Institute, NIH, Department of Health and Human Services. Funding for the USC study was received from the California Cancer Research Program grants 00-01389V-20170 and 2110200, U.S. Public Health Service grants CA14089, CA17054, CA61132, CA63464, N01-PC-67010 and R03-CA113148, and California Department of Health Services sub-contract 050-E8709 as part of its statewide cancer reporting program (University of Southern California). The HJO study gratefully acknowledges the contribution of Drs. Frauke Kramer and Wen Zheng to the recruitment of patients at Hannover Medical School. The HMO study gratefully acknowledges the help of Lena Gacucova in sample preparation. The HOC study has been financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland and the Finnish Cancer Society.

References

1. Song H, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nat Genet* 2009;41:996–1000. [PubMed: 19648919]
2. Yeager M, et al. Identification of a new prostate cancer susceptibility locus on chromosome 8q24. *Nat Genet* 2009;41:1055–7. [PubMed: 19767755]
3. Gudmundsson J, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1122–6. [PubMed: 19767754]
4. Al Olama AA, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nat Genet* 2009;41:1058–60. [PubMed: 19767752]
5. Tenesa A, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. *Nat Genet* 2008;40:631–7. [PubMed: 18372901]
6. Ghousaini M, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. *J Natl Cancer Inst* 2008;100:962–6. [PubMed: 18577746]
7. Kiemeny LA, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. *Nat Genet* 2008;40:1307–12. [PubMed: 18794855]
8. Jia L, et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. *PLoS Genet* 2009;5:e1000597. [PubMed: 19680443]
9. Pomerantz MM, et al. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. *Nat Genet* 2009;41:882–4. [PubMed: 19561607]
10. Katoh M, Katoh M. Identification and characterization of human TIPARP gene within the CCNL amplicon at human chromosome 3q25.31. *Int J Oncol* 2003;23:541–7. [PubMed: 12851707]
11. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. *Nature* 2005;434:917–21. [PubMed: 15829967]
12. Fong PC, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. *N Engl J Med* 2009;361:123–34. [PubMed: 19553641]
13. Ma Q, Baldwin KT, Renzelli AJ, McDaniel A, Dong L. TCDD-inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Biochem Biophys Res Commun* 2001;289:499–506. [PubMed: 11716501]
14. Buzzai M, Licht JD. New molecular concepts and targets in acute myeloid leukemia. *Curr Opin Hematol* 2008;15:82–7. [PubMed: 18300752]

15. Shiraishi M, Sekiguchi A, Oates AJ, Terry MJ, Miyamoto Y. HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. *Oncogene* 2002;21:3659–62. [PubMed: 12032868]
16. Jacinto FV, Ballestar E, Ropero S, Esteller M. Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells. *Cancer Res* 2007;67:11481–6. [PubMed: 18089774]
17. Okubo Y, et al. Transduction of HOXD3-antisense into human melanoma cells results in decreased invasive and motile activities. *Clin Exp Metastasis* 2002;19:503–11. [PubMed: 12405287]
18. Fang L, Seki A, Fang G. SKAP associates with kinetochores and promotes the metaphase-to-anaphase transition. *Cell Cycle* 2009;8:2819–27. [PubMed: 19667759]
19. Kosco KA, Cerignoli F, Williams S, Abraham RT, Mustelin T. SKAP55 modulates T cell antigen receptor-induced activation of the Ras-Erk-AP1 pathway by binding RasGRP1. *Mol Immunol* 2008;45:510–22. [PubMed: 17658605]
20. Lakhani SR, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. *Clin Cancer Res* 2004;10:2473–81. [PubMed: 15073127]
21. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007;447:661–78. [PubMed: 17554300]
22. Tomlinson IP, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. *Nat Genet* 2008;40:623–30. [PubMed: 18372905]
23. Udler MS, et al. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. *Hum Mol Genet* 2009;18:1692–703. [PubMed: 19223389]
24. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. *Am J Hum Genet* 2008;82:290–303. [PubMed: 18252211]
25. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;21:1539–1558. [PubMed: 12111919]
26. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7:177–88. [PubMed: 3802833]
27. Li NF, et al. A modified medium that significantly improves the growth of human normal ovarian surface epithelial (OSE) cells in vitro. *Lab Invest* 2004;84:923–31. [PubMed: 15077121]
28. Lawrenson K, et al. Senescent fibroblasts promote neoplastic transformation of ovarian epithelial cells in a three-dimensional model of early stage ovarian cancer. *Neoplasia*. in press.
29. Lawrenson K, et al. In vitro three-dimensional modelling of human ovarian surface epithelial cells. *Cell Prolif* 2009;42:385–93. [PubMed: 19397591]




Figure 1.

Genomic architecture of the four novel ovarian cancer susceptibility regions identified from the EOC-GWAS. Key: Clear triangles- the location of SNP with the most statistically significant association at each locus; Grey triangles- the location of SNPs correlated with the associated SNP with $r^2 > 0.8$ (a) The 8q24.21 locus: the most significant SNP (rs10088218) lies $>700\text{kb}$ distal to *CMYC* in an otherwise 'gene desert'. Lower resolution map: rs10088218 is located with respect to 13 other SNPs (black triangles) significantly associated with susceptibility to prostate cancer (PrC), colorectal cancer (CrC), breast cancer (BrC), urinary bladder cancer (UBC) and renal disease (ReD). Higher magnification map: rs10088218 is located with respect to 10 other HapMap SNPs correlated with rs10088218 (b) The most significant SNP at 3q25.31 (rs2665390) lies within *TiPARP*, the only gene within a $\sim 200\text{kb}$ region spanning this SNP. Higher resolution map: rs2665390 location with respect to the only other highly correlated HapMap SNP, which is also in *TiPARP*. (c) 2q31.1 contains the *HOXD* gene family. The most significantly associated SNP (rs2072590) lies in a non-coding region $\sim 5\text{kb}$ distal to *HOXD3* and $\sim 10\text{kb}$ proximal to *HOXD1*. Higher resolution map: The location of rs2072590 with respect to two correlated SNPs, one 3' of *HOXD3*, the other distal to *HOXD4*. (d) 17q21.31 contains rs9303542, which is located in the intron of *SKAP1*, which lies distal to the *HOXB* family of transcription factors. This SNP is correlated with several other SNPs all located in *SKAP1*.




Figure 2.

Gene expression analysis for five candidate EOC susceptibility genes: **(a)** *BNC2* (9p22); **(b)** *TiPARP* (3q25); **(c)** *CMYC* expression (8q24); **(d)** *HOXD1* (2q31), and **(e)** *SKAP1* (17q21). Two different types of analysis are shown: the first panel of each pair shows real time RT-PCR analysis of each gene comparing gene expression between 48 POE and 24 OC cell lines. Gene expression is shown as normalised against β -actin. Expression was also normalized against GAPDH, which gave similar results (supplementary figure 2). Error bars show standard deviation. The second panel of each pair shows expression microarray data from an *in vitro* stepwise model of neoplastic transformation POE cells. Briefly, gene expression in immortalised POE (iOE) cells, versus iOE^{cmyc} cells overexpressing *CMYC*,

verses iOE^{cm_{yc}.kras} cells overexpressing *CMYC* and mutant *KRAS*. **(a)** *BNC2* expression is significantly lower in OC cell lines versus normal POE cells for both endogenous controls. In the model of neoplastic transformation, *BNC2* expression decreases significantly with each additional oncogenic event, as the cells acquire a more neoplastic phenotype. **(b)** *TiPARP* shows significantly reduced expression in OC cells compared to POE cells for both endogenous controls; *TiPARP* expression also decreases sequentially in the neoplastic transformation model. **(c)** *CMYC* expression is significantly increased in OC compared to POE cells for both endogenous controls and increases in the transforming cell line model. **(d)** Expression of *HOXD3* and *HOXD1* was evaluated. *HOXD3* expression was too low to draw reliable conclusions. *HOXD1* increased in OC compared POE cells, suggesting activation in OC development. **(e)** *SKAP1* expression was significantly greater in OC compared to POE cells. A trend towards increased expression was also observed in progressively transforming iOE cells.

Table 1

Overview of GWAS Study Design

| Phase | N Studies | Study population | Genotyping method | N SNPs genotyped | N SNPs passed QC | N SNPs including imputed | N Cases | N Controls |
|---------------|-----------|--------------------------------|---|------------------|------------------|--------------------------|---------|------------|
| Phase I | 6 | UK | Illumina 610K/Illumina 550K | 620,901 | 507,094 | 2,056,878 | 1,768 | 2,354 |
| Phase II | 12 | Europe, USA, Australia | Illumina iSelect | 23,590 | 21,955 | 21,955 | 4,162 | 4,810 |
| Phase III | 16 | Europe, USA, Canada, Australia | iPlex/Taqman/Illumina 610K/Illumina 317K | 30 | 30 | 30 | 4,353 | 6,021 |
| Meta-Analysis | 1 | Iceland | Centaurus, Illumina 317K, Illumina HumanCNV37 0-duo | 11 | 11 | 11 | 194 | 40,933 |
| | | | | Total | 10,477 | 54,118 | | |

Table 2

SNP Associations at Four Novel Loci

| Locus | SNP | Set | Cases | Controls | OR (95% CI) | p | p-het |
|-------|----------------|--------------|--------|----------|-------------------------|-----------------------------|----------------------------|
| 2q31 | rs2072590 G>T | Phase I | 1,768 | 2,354 | 1.16 (1.05,1.27) | 2.1×10 ⁻³ | |
| | | Phase II | 4,162 | 4,810 | 1.12 (1.05,1.19) | 4.4×10 ⁻⁴ | 0.17 |
| | | Phase III | 4,342 | 6,001 | 1.19 (1.12,1.26) | 1.9×10⁻⁸ | |
| | | Combined | 10,406 | 16,340 | 1.16 (1.12,1.21) | 4.5×10⁻¹⁴ | |
| | | Serous | 5,925 | 16,340 | 1.20 (1.14,1.25) | 3.8×10⁻¹⁴ | |
| | | Endometrioid | 1,595 | 16,340 | 1.13 (1.04,1.22) | 2.4×10 ⁻³ | 2.9×10⁻⁴ |
| | | Mucinous | 796 | 16,340 | 1.30 (1.17,1.44) | 7.3×10 ⁻⁷ | |
| | | Clear Cell | 731 | 16,340 | 0.97 (0.87,1.09) | 0.59 | |
| | | Phase I | 1,768 | 2,354 | 1.15 (0.98,1.34) | 0.08 | |
| | | Phase II | 4,162 | 4,810 | 1.23 (1.11,1.36) | 8.2×10 ⁻⁵ | 0.24 |
| 3q25 | rs2665390 T>C | Phase III | 4,285 | 5,953 | 1.19 (1.07,1.34) | 1.8×10 ⁻³ | |
| | | Combined | 10,406 | 17,369 | 1.19 (1.11,1.27) | 3.2×10⁻⁷ | |
| | | Serous | 5,896 | 17,369 | 1.24 (1.15,1.34) | 7.1×10⁻⁸ | |
| | | Endometrioid | 1,595 | 17,369 | 1.23 (1.08,1.40) | 1.9×10 ⁻³ | 0.02 |
| | | Mucinous | 789 | 17,369 | 1.02 (0.84,1.23) | 0.85 | |
| | | Clear Cell | 726 | 17,369 | 1.12 (0.92,1.35) | 0.26 | |
| | | Phase I | 1,768 | 2,354 | 0.85 (0.74,0.97) | 0.02 | |
| | | Phase II | 4,162 | 4,810 | 0.89 (0.81,0.97) | 0.01 | 0.34 |
| | | Phase III | 4,339 | 6,007 | 0.79 (0.73,0.87) | 2.8×10⁻⁷ | |
| | | Combined | 10,462 | 16,362 | 0.84 (0.80,0.89) | 3.2×10⁻⁹ | |
| 8q24 | rs10088218 G>A | Serous | 5,917 | 16,362 | 0.76 (0.70,0.81) | 8.0×10⁻¹⁵ | |
| | | Endometrioid | 1,607 | 16,362 | 0.95 (0.85,1.06) | 0.36 | 1.1×10⁻⁷ |
| | | Mucinous | 796 | 16,362 | 0.90 (0.77,1.05) | 0.18 | |
| | | Clear Cell | 731 | 16,362 | 1.21 (1.05,1.40) | 0.01 | |
| | | Phase I | 1,768 | 2,354 | 1.20 (1.08,1.32) | 5.3×10 ⁻⁴ | 0.27 |

| Locus | SNP | Set | Cases | Controls | OR (95% CI) | p | p-het |
|-------|-----|--------------|--------|----------|-------------------------|----------------------------|-------|
| | | Phase II | 4,158 | 4,806 | 1.14 (1.06,1.21) | 1.5×10 ⁻⁴ | |
| | | Phase III | 4,316 | 5,931 | 1.05 (0.99,1.12) | 0.13 | |
| | | Combined | 10,242 | 13,091 | 1.11 (1.06,1.16) | 1.4×10 ⁻⁶ | |
| | | Serous | 5,814 | 13,091 | 1.14 (1.09,1.20) | 1.4×10⁻⁷ | |
| | | Endometrioid | 1,573 | 13,091 | 1.09 (1.00,1.18) | 0.05 | 0.11 |
| | | Mucinous | 766 | 13,091 | 1.03 (0.91,1.15) | 0.66 | |
| | | Clear Cell | 715 | 13,091 | 1.05 (0.90,1.15) | 0.77 | |

OR, per-allele odds ratio; 95% CI, confidence interval; Phase I and Phase II adjusted for study site and first principal component; note that rs2665390 and rs10088218 were selected for Phase III based on combined results across phases in serous cases (data not shown); Phase III adjusted for study site; ICE data are included for combined analysis of rs2072590, rs2665390, and rs10088218 using meta-analytic techniques; no consistent patterns of heterogeneity were found when including ICE data and so only fixed effects meta-analysis results are presented; p-het represents heterogeneity test across all studies for combined analyses of all phases and, for subtype analyses, across subtypes excluding the ICE study; endometrioid, mucinous, and clear cell analyses are not adjusted for study; bold indicates association p<10⁻⁷ and heterogeneity p<0.05.